Effects of GSK3β/eEF2K signaling pathway on pulmonary fibrosis in mice

doi:10.12047/j.cjap.6201.2022.006

Abstract

Abstract: Objective: To investigate the effects of glycogen synthase kinase-3β (GSK3β)/eukaryotic extension factor kinase 2 (eEF2K) signaling pathway on the process of pulmonary fibrosis through in vivo experiments, and find new ideas for clinical treatment of pulmonary fibrosis. Methods: The pulmonary fibrosis model of C57BL/6 male mice was induced by bleomycin with intratracheal injection at the dose of 2 mg/kg. After 14 days of modeling, animals were divided into model group, negative inhibition group and inhibition group (n=5 for each group), and control group was not processed. The inhibition group was treated with TDZD-8 (4 mg/kg) after modeling, the negative inhibition group was given DMSO solution after modeling, and the samples were collected after 28 days. Hematoxylin-eosin staining method was used to detect lung fibrosis in mice and scored according to Ashcroft scale. Expression levels of GSK3β, p-GSK3β, eEF2K, p-eEF2K (Ser70, Ser392, Ser470), precursor protein of matrix metalloproteinase-2 (pro-MMP-2), matrix metalloproteinase-2 (MMP-2), collagen I (Col I), collagen Ⅲ (Col Ⅲ) and α-smooth muscle actin (α-SMA) were detected by Western blot. Results: Compared with control group, the fibrosis score was up-regulated, the expression levels of GSK3β, p-GSK3β, p-eEF2K (Ser70, Ser392, Ser470), pro-MMP-2, MMP-2, Col I, Col Ⅲ and α-SMA were increased, while that of eEF2K was decreased in model group (P＜0.05). Compared with model group, the fibrosis score, expression levels of GSK3β, p-GSK3β, p-eEF2K (Ser70, Ser392, Ser470), pro-MMP-2, MMP-2, Col I, Col Ⅲ and α-SMA were decreased, but the expression level of eEF2K was increased in inhibition group (P＜0.05). Conclusion: GSK3β can activate eEF2K by phosphorylation at the sites of Ser70, Ser392 and Ser470, increase the contents of fibrosis indicators, promote the formation of pulmonary fibrosis, and aggravate lung tissue lesions.

Key words: pulmonary fibrosis, mice, GSK3β/eEF2K, MMP-2, TDZD-8

CLC Number:

R563

QIN Chao-qun, HUANG Bin, YANG Fang, WANG Chang-ming, XIAO Ying, MO Yan-ju, LIAO Yi, GAO Feng. Effects of GSK3β/eEF2K signaling pathway on pulmonary fibrosis in mice[J]. CJAP, 2022, 38(1): 32-36.

References

[1] Varone F, Mastrobattista A, Franchi P, et al. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone[J]. Clin Respir J, 2018, 12(1): 347-351.
[2] Kim HS, Yoo HJ, Lee KM, et al. Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis[J]. Respirology, 2020, 26(3): 255-263.
[3] Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria[J]. Am J Respir Crit Care Med, 2017, 195(1): 78-85.
[4] Birjandi SZ, Palchevskiy V, Xue YY, et al. CD4(+)CD25(hi)Foxp3(+) cells exacerbate bleomycin-induced pulmonary fibrosis[J]. Am J Pathol, 2016, 186(8): 2008-2020.
[5] Proud CG. Regulation and roles of elongation factor 2 kinase[J]. Biochem Soc Trans, 2015, 43(3): 328-332.
[6] Kameshima S, Kazama K, Okada M, et al. Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling[J]. Am J Physiol Heart Circ Physiol, 2015, 308(10): 1298-1305.
[7] Gurrieri C, Piazza F, Gnoato M, et al. 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis[J]. J Pharmacol Exp Ther, 2010, 332(3): 785-794.
[8] Greco F, Wiegert S, Baumann P, et al. Hyperoxia-induced lung structure-function relation, vessel rarefaction, and cardiac hypertrophy in an infant rat model[J]. J Transl Med, 2019, 17(1): 91.
[9] Ni S, Wang D, Qiu X, et al. Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling[J]. Int J Clin Exp Pathol, 2015, 8(7): 7752-7761.
[10] Zhou XL, Xu P, Chen HH, et al. Thalidomide inhibits TGF-β1-induced epithelial to mesenchymal transition in alveolar epithelial cells via Smad-dependent and Smad-independent signaling pathways[J]. Sci Rep, 2017, 7(1): 14727.
[11] Keller JL, Housh TJ, Hill EC, et al. The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels[J]. J Int Soc Sports Nutr, 2019, 16(1): 3.
[12] Fu Y, Zhao P, Xie Z, et al. Oridonin inhibits myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by regulating transforming growth factor β (TGFβ)/Smad pathway[J]. Med Sci Monit, 2018, 24(1): 7548-7555.
[13] 陈彦凡, 何以成, 黄卡特, 等. 腺苷A_(2a)受体在博莱霉素诱导的小鼠肺纤维化中的作用[J]. 中国应用生理学杂志, 2018, 34(3): 204-208.
[14] Srivastava AK, Khare P, Nagar HK, et al. Hydroxyproline: A potential biochemical marker and its role in the pathogenesis of different diseases[J]. Curr Protein Pept Sci, 2016, 17(6): 596-602.
[15] 卢林明, 俞婷婷, 何晓伟, 等. 小剂量辣椒素抗小鼠肺纤维化的作用及其机制[J]. 中国应用生理学杂志, 2020, 36(3): 216-222.
[16] Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting[J]. FEBS J, 2011, 278(1): 16-27.
[17] Cheng MH, Wong YH, Chang CM, et al. B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB[J]. Int J Mol Med, 2017, 39(5): 1137-1148.
[18] 肖雪, 李龙. 基质金属蛋白酶与特发性肺纤维化关系研究进展[J]. 河北医药, 2020, 42(22): 3462-3467.
[19] Karakas D, Ozpolat B. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target[J]. J Mol Med (Berl), 2020, 98(6): 775-787.
[20] Moore CE, Wang X, Xie J, et al. Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy[J]. Cell Signal, 2016, 28(4): 284-293.
[21] Wang Y, Huang G, Wang Z, et al. Elongation factor-2 kinase acts downstream of p38 MAPK to regulate proliferation, apoptosis and autophagy in human lung fibroblasts[J]. Exp Cell Res, 2018, 363(2): 291-298.
[22] Liu R, Proud CG. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases[J]. Acta Pharmacol Sin, 2016, 37(3): 285-294.
[23] Bircan HA, Gurbuz N, Pataer A, et al. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer[J]. Lung Cancer, 2018, 124: 31-39.
[24] Wang X, Regufe Da Mota S, Liu R, et al. Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling[J]. Mol Cell Biol, 2014, 34(22): 4088-4103.
[25] 许春花, 王永双, 金福, 等. 西地那非通过AKT/GSK3β信号通路保护小鼠肾纤维化的作用机制[J]. 医学研究生学报, 2020, 33(6): 592-597.
[26] Beretta S, Gritti L, Verpelli C, et al. Eukaryotic elongation factor 2 kinase a pharmacological target to regulate protein translation dysfunction in neurological diseases[J]. Neuroscience, 2020, 445(1): 42-49.